Proteomics advances for precision therapy in ovarian cancer. (3rd October 2019)

• Record Type: Journal Article
• Authors: Labrie, Marilyne; Kendsersky, Nicholas D; Ma, Hongli; Campbell, Lydia; Eng, Jennifer; Chin, Koei; Mills, Gordon B
• Is Part Of: Expert review of proteomics. Volume 16:Number 10(2019)
• Page Start: 841
• Page End: 850
• Publication Date: 2019-10-03
• Subjects: Ovarian cancer -- proteomics -- adaptive responses; Proteins -- Biotechnology -- Periodicals; Proteomics -- Periodicals; 572.6
• DOI: 10.1080/14789450.2019.1666004
• Languages: English
• ISSNs: 1478-9450

Abstract

ABSTRACT: Introduction : Due to the relatively low mutation rate and high frequency of copy number variation, finding actionable genetic drivers of high-grade serous carcinoma (HGSC) is a challenging task. Furthermore, emerging studies show that genetic alterations are frequently poorly represented at the protein level adding a layer of complexity. With improvements in large-scale proteomic technologies, proteomics studies have the potential to provide robust analysis of the pathways driving high HGSC behavior. Areas covered : This review summarizes recent large-scale proteomics findings across adequately sized ovarian cancer sample sets. Key words combined with 'ovarian cancer' including 'proteomics', 'proteogenomic', 'reverse-phase protein array', 'mass spectrometry', and 'adaptive response', were used to search PubMed. Expert opinion : Proteomics analysis of HGSC as well as their adaptive responses to therapy can uncover new therapeutic liabilities, which can reduce the emergence of drug resistance and potentially improve patient outcomes. There is a pressing need to better understand how the genomic and epigenomic heterogeneity intrinsic to ovarian cancer is reflected at the protein level and how this information could be used to improve patient outcomes.